EMYRIA LIMITED — AGM Information 2020

Sep 29, 2020

==> picture [596 x 148] intentionally omitted <==

ASX/Media Release 30 September 2020

Annual General Meeting Date

Emerald Clinics Limited (ASX: EMD) (Emerald or the Company), a Real-World Evidence data company that develops remote patient monitoring technologies advises, in accordance with ASX Listing Rule 3.13.1, that it has scheduled the Annual General Meeting (AGM) of the Company to be held on 13 November 2020.

An item of business at the AGM will be the re-election of directors. The closing date for the receipt of director nominations is Wednesday , 7 October 2020.

Nominations must be received at the Company’s registered office no later than 5.00pm (Perth time) on Wednesday 7 October 2020.

Release authorised by:

Dr Michael Winlo, Managing Director

For further information:

Dr Michael Winlo Matt Wright Managing Director Media/investor relations (08) 6559 2800 +61 (0) 451 896 420 investors@emyria.com matt@nwrcommunications.com.au

About Emyria Limited

Emyria Limited (ACN 625 085 734) is an Australian incorporated company that operates a network of specialist medical clinics (Clinics) and uses purpose-built software and technology to gather high quality clinical data from informed and consenting patients to create robust and ethically-sourced evidence.

Emyria is a clinical services and healthcare technology company focussed on the provision of care for patients clinically determined to have exhausted conventional therapies and who may be suitable for cannabinoid-based medicines. In addition, Emyria uses technology to capture clinical data that can be used to generate clinical evidence relating to the safety and efficacy of unregistered medicines. Emyria has established four medical centres in Australia in Perth, Sydney, Melbourne and Northern Rivers NSW.

==> picture [595 x 65] intentionally omitted <==

==> picture [596 x 72] intentionally omitted <==

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a results of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.